What's in the Pipeline? Prospects for Monoclonal Antibodies (mAbs) as Therapies for Lung Diseases

Author： Li L.   Das A.M.   Torphy T.J.   Griswold D.E.  

Publisher： Academic Press

ISSN： 1094-5539

Source： Pulmonary Pharmacology & Therapeutics, Vol.15, Iss.5, 2002-10, pp. : 409-416

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The monoclonal antibodies (mAbs) 2F5 and 2G12 show antiviral activity in patients with HIV-1 infection

By  

Inpharma, Vol. 1, Iss. 1364, 2002-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases

By  

Current Pharmaceutical Design, Vol. 18, Iss. 29, 2012-10 ,pp. : 4498-4507

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal antibodies for prophylaxis and therapy of infectious diseases

By Meulen Jan ter  

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 4, 2007-11 ,pp. : 525-540

Informa Healthcare

Access to resources Recommend Favorite

Human HLA-DR mAbs promising against lymphoma

By  

Inpharma, Vol. 1, Iss. 1355, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Human monoclonal antibodies to IFN-α for the treatment of autoimmune diseases

By  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 2, 2006-02 ,pp. : 221-226

Informa Healthcare

Access to resources Recommend Favorite